Centre Hospitalier De Versailles
- Address
- lock Available on a paid plan
Centre Hospitalier De Versailles - Comprehensive Research in Hematology and Critical Care
The Centre Hospitalier De Versailles is a leading academic medical center with extensive expertise in hematologic malignancies and critical care medicine. The center demonstrates particular strength in the evaluation of novel therapeutic combinations and targeted therapies for complex blood disorders, alongside pioneering work in intensive care management and infectious disease treatment strategies.
- Advanced leukemia and lymphoma research, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes, chronic myeloid leukemia, and various T-cell and B-cell lymphomas
- Critical care innovations in sepsis management, cardiac arrest resuscitation, mechanical ventilation, and hemodynamic support strategies
- Cardiovascular research focusing on acute myocardial infarction, heart failure prevention, and lipid management
- Infectious disease trials evaluating antibiotic strategies, antiviral treatments, and antifungal therapies in immunocompromised populations
The center's research portfolio encompasses multiple phase II and III trials investigating immunotherapies, targeted molecular agents, and combination regimens across a broad spectrum of conditions. Special emphasis is placed on precision medicine approaches, including biomarker-driven patient selection and adaptive trial designs. The facility maintains strong capabilities in both oncologic and non-oncologic research, with particular expertise in studying rare diseases such as Kawasaki disease, familial Mediterranean fever, and hemophagocytic lymphohistiocytosis, while also contributing to large-scale studies in metabolic disorders and pulmonary conditions like sarcoidosis and non-tuberculous mycobacterial infections.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 15 therapeutic areas and 15 of 214 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 178 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 38 by active trials.
lock +37 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +23 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier De Versailles
lock Showing 1 of 122 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicentre, double-blind, randomized controlled trial of inhaled amikacin versus placebo in critically ill patients with ventilator-associated tracheobronchitis (AMIVAT) | Centre Hospitalier Regional Universitaire De Tours | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 214 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azacitidine | 10 | Unknown | 2019-03-20 | 2026-03-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.